NORFOLK, VA – November 11, 2010 – Genomind, LLC presented “Biomarkers in the Management of Depression” at the 2010 NEI Global Psychopharmacology Congress (www.neiglobal.com) on November 11, 2010. The annual Congress convenes hundreds of mental health professionals and is being held at The Broadmoor Hotel in Colorado Springs, CO on November 11-14. The Genomind presentation addressed new developments in psychiatry that include identification of key molecular biomarkers which can help guide physicians treating patients with depression, and was featured as NEI’s first Product Theatre.
Presenters for Genomind included: Jay Lombard, DO, Assistant Clinical Professor of Neurology, New York Presbyterian Hospital; Chief Scientific Officer for Genomind, LLC; Roy Perlis, MD, MSc, Medical Director of the Bipolar Clinic and Research Program and Director of Psychiatric Pharmacogenomics Research at the Massachusetts General Hospital; Associate Professor, Harvard Medical School; Scientific Advisory Board Member, Genomind, LLC; and Nancy Grden, General Manager, Genomind, LLC.
Genomind also hosted a booth (#19-20) in the NEI Congress Exhibit Hall.
(This promotional activity was provided by Genomind, LLC and is not certified for continuing education credit. The content of the Product Theater and opinions expressed by presenters are those of the sponsor or presenters and not of the Neuroscience Education Institute.)
About Genomind, LLC
Genomind, LLC is a company specializing in neuropsychiatric personalized medicine and was formed to facilitate the adoption of Personalized Medicine into psychiatry by assisting physicians in the selection of appropriate medicine based on genetic information. Genomind was founded by Ronald I. Dozoretz, MD, in 2009, and the company is advised by a group of renowned experts in the fields of human genetics and neuropsychiatric medicine. More information is available at: www.genomind.com.